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We examined Escherichia coli and Klebsiella spp. from
US hospitals for class 1 integrons. Of 320 isolates, 181
(57%) were positive; association of integrons with resistance
varied by drug and organism. Thus, determining integron
epidemiology will improve understanding of how antibacteri-
al resistance determinants spread in the United States.
I
ntegrons are genetic elements, located on the bacterial
chromosome or a plasmid, that often carry genetic deter-
minants for antimicrobial drug resistance (1). The need for
systematic epidemiologic studies of the role of integrons in
antimicrobial drug resistance in bacteria has recently been
emphasized (2). The prevalence of integrons is high
among gram-negative isolates from patients in Europe
(3,4), and some carry multiple integrons (3). Reports from
Asian countries also have noted a high prevalence of class
I integrons in gram-negative clinical isolates (5). Most of
the resistance integrons found to date in clinical isolates of
Enterobacteriaceae are class 1 integrons, which are highly
associated with resistance to antimicrobial agents (2).
These data suggest that integrons are relatively com-
mon, especially among the Enterobacteriaceae, and that
they contribute to the spread of antimicrobial drug resist-
ance in healthcare settings. However, few studies from the
United States have assessed the association between inte-
gron carriage and antimicrobial susceptibility patterns.
This study analyzes the association between class 1
integrons and resistance to selected antimicrobial agents in
a convenience sample of Escherichia coli and Klebsiella
isolates. Multivariate analysis was used to determine
whether apparent associations were affected by interac-
tions between variables. Isolates were submitted from hos-
pitals participating in Project ICARE (Intensive Care
Antimicrobial Resistance Epidemiology) (6). The protocol
has been approved as exempt by the institutional review
board at Emory University.
The Study
Clinical isolates of E. coli, Klebsiella pneumoniae, and
K. oxytoca were obtained from 19 US hospitals during
phase IV (2002–2004) of Project ICARE, which focused
on nonoutbreak isolates of Enterobacteriaceae with
decreased susceptibility to extended-spectrum
cephalosporins, fluoroquinolones, or carbapenems. The 19
hospitals were located in 13 states throughout the country
and had an approximately equal mix of teaching and non-
teaching medical centers. Duplicate isolates from the same
patient were excluded.
Isolates were tested for susceptibility to the antimicro-
bial drugs listed in Table 1 by using the broth microdilu-
tion reference method (BMD) described by the Clinical
and Laboratory Standards Institute (7). Isolates were
stored at −70°C and were subcultured to trypticase soy
agar plates containing 5% defibrinated sheep blood (BD
BioSciences, Sparks, MD, USA) >2 times before testing.
For each organism, BMD tests were inoculated by using a
cell suspension equivalent to a 0.5 McFarland standard.
Enterobacteriaceae isolate identifications provided by par-
ticipating laboratories were confirmed by colony shape,
spot tests (8), and Vitek GNI+ cards (bioMérieux, Durham,
NC, USA). Differences were resolved by using reference
biochemical tests (9).
Isolates were analyzed by polymerase chain reaction
(PCR) amplification techniques to determine whether a
class 1 integron was present. Integrons were detected by
PCR amplification of a class 1 integrase–specific fragment
of the IntI1 gene as previously described (1). The primer
sequences used were IntI1-F: 5′-TCT CGG GTA ACA
TCAAGG-3′ and IntI1-R: 5′-AGG AGATCC GAA GAC
CTC-3′.
Amplifications were performed in 10 µL of Taq PCR
Master Mix (Qiagen, Valencia, CA, USA), 1.5 mmol/L
MgCl2, 5 pmol/L each primer, and 1 µg template DNA(1).
DNA was extracted with a Genelite Bacterial Genomic
DNA Kit (Sigma, Saint Louis, MO, USA). Amplification
specifications were as follows: 5 min at 94°C followed by
35 cycles of 1 min at 94°C, 1 min at 55°C, and 30 s at
72°C. PCR products were analyzed by gel electrophoresis
with 1.5% agarose gels. All PCRs included positive and
negative controls.
A statistical comparison of the frequencies of integron
presence in E. coli and Klebsiella spp. was conducted by
using odds ratios and 95% confidence intervals.
Intermediate and resistant isolates were pooled as nonsus-
ceptible for analysis. Multivariate logistic regression
analysis was conducted with 1 representative from each
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were performed by SAS statistical software version 9.1
(SAS Institute, Cary, NC, USA). Fit of the data to this
model was evaluated by the Hosmer-Lemeshow χ2 test.
Apositive test result for class 1 integrons was found for
181 (57%) of the 320 bacterial isolates screened, including
103 (49%) of 209 E. coli isolates and 78 (70%) of 111
Klebsiella spp. isolates. A positive test result in E. coli iso-
lates was significantly associated with nonsusceptibity to
gentamicin, tobramycin, ciprofloxacin, chloramphenicol,
and trimethoprim-sulfamethoxazole (Table 1). A positive
test result in Klebsiella isolates was significantly associated
with nonsusceptibility to gentamicin, tobramycin, cefpo-
doxime, ceftazidime, and trimethoprim-sulfamethoxazole.
Multivariate analysis showed that the only drug vari-
ables associated with a positive test result for class 1 inte-
grons in E. coli were nonsusceptibility to gentamicin and
trimethoprim-sulfamethoxazole (with a strong interaction
between the 2 variables), while an inverse association was
present between a positive integron test result and nonsus-
ceptibility to cefepime (Table 2). For Klebsiella spp., a
positive association existed between a positive integron
test result and nonsusceptibility to gentamicin and
trimethoprim-sulfamethoxazole, as well as an inverse
association between a positive integron test result and non-
susceptibility to aztreonam.
Conclusions
More than half of the selected isolates from US hospi-
tals that we tested were positive for class 1 integrons. The
prevalence of class 1 integrons in E. coli was 49% in select-
ed non-outbreak isolates from hospitalized patients from
2002 to 2004 in our study, 52% in consecutive urinary tract
isolates in 2001 in Sweden (10), and 15% in isolates from
blood in hospitals in Sweden in 1998 and 1999 (11). The
prevalence of integrons was 70% in Klebsiella isolates
from hospitalized patients in our study and 73% in extend-
ed-spectrum  β-lactamase (ESBL)–producing Klebsiella
spp. collected from 3 hospitals in Australia from 1989 to
1999 (12). These data cannot be directly compared because
of differences in selection criteria and testing procedures,
but as a whole they suggest that prevalence of integrons in
these bacteria in the United States is high, as it is in other
areas of the world. Carbapenem resistance was infrequent
in the isolates we tested, so we could not address the asso-
ciation of integron carriage and metallo-β-lactamases that
has been observed in other parts of the world (2).
Our study found an inverse association between inte-
gron presence and nonsusceptibility to cefepime in E. coli
and to aztreonam in Klebsiella spp., which indicates that
resistance determinants for these drugs are not frequently
carried by integrons. One possible reason for the lack of an
association between nonsusceptibility to cefepime and
integron carriage is the relatively recent approval of
cefepime for use in the United States. CTX-M-type β-lac-
tamases are the most common resistance determinants in
cefepime-resistant isolates worldwide, but these enzymes
are just beginning to appear in the United States (13).
In phase IV of Project ICARE, participating sites were
asked to submit isolates that showed decreased susceptibil-
ity to fluoroquinolones, extended-spectrum cephalo-
sporins, or carbapenems. We did not track whether isolates
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isolates made up a convenience sample strongly associat-
ed with drug resistance mechanisms carried as integron
gene cassettes and otherwise, and they are not necessarily
representative of isolates from the United States in gener-
al. We did not examine carriage of >1 integron, as docu-
mented in earlier studies (10).
In these selected isolates, the crude association between
a positive test result for class 1 integrons and nonsuscepti-
bility to a fluoroquinolone (ciprofloxacin) in E. coli, and
nonsusceptibility to a β-lactam (ceftazidime) in Klebsiella
spp. failed to remain as independent variables in the mul-
tivariate model. This finding suggests that the mechanisms
of resistance to fluoroquinolones and β-lactams are associ-
ated with mechanisms of resistance to the drugs that
remained independently associated with class 1 integrons
(aminoglycosides and trimethoprim-sulfamethoxazole),
but for reasons unrelated to integron carriage. A previous
study also found that ciprofloxacin resistance no longer
predicted integron presence in Enterobacteriaceae when
multivariate analysis was conducted (1). A Spanish study
(14) found no association between integron carriage and β-
lactam resistance in ESBL-producing E. coli strains unless
strains contained metallo-β-lactamases, which were infre-
quently encountered in our study population. A biologic
mechanism for association of resistance to fluoro-
quinolones and aminoglycosides (i.e., the inactivation of
ciprofloxacin by the aac(6′)-Ib-cr aminoglycoside acety-
lating gene) has been recently reported. (15).
In our study, both crude and multivariate associations
between integron positivity and nonsusceptibility varied
for the E. coli and Klebsiella groups. This finding empha-
sizes that studies of this type must assess whether analysis
should combine results for organisms of different genus
and species into larger groups (e.g., Enterobacteriaceae).
When determinants encoding resistance to a variety of
antimicrobial classes are contained within an integron, use
of any of these agents may select for and enhance expres-
sion of the other determinants (2). Thus, in the example of
our studied isolates, use of aminoglycosides may lead to
spread of a multidrug-resistant bacterial strain such as K.
pneumoniae. The differential association of class 1 inte-
grons with resistance in the isolates we studied suggests
that integrons facilitate the spread of antimicrobial drug
resistance in the United States.
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